FTC Pay-For-Delay Stats Show Androgel Stakes Are High

Law360, New York (January 17, 2013, 9:48 PM EST) -- Branded pharmaceutical companies and generic-drug makers have inked a record high number of potentially anti-competitive patent settlements over the past fiscal year, the Federal Trade Commission said Thursday, underscoring how much is at stake in the U.S. Supreme Court's upcoming pay-for-delay case.

The number of so-called pay-for-delay deals, in which branded-drug makers compensate generic-drug companies for delaying market entry to settle Hatch-Waxman Act patent litigation, has been creeping steadily upward since the agency started monitoring the settlements in 2003. But the total of 40 for the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.